2-benzyloxy-3-oxo-propionic acid ethyl ester | 100117-99-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-benzyloxy-3-oxo-propionic acid ethyl ester
• 英文别名: 2-Benzyloxy-3-oxo-propionsaeure-aethylester；ethyl 2-(benzyloxy)-3-oxopropanoate；ethyl 3-oxo-2-phenylmethoxypropanoate
• CAS: 100117-99-5
• 化学式: C₁₂H₁₄O₄
• 分子量: 222.241
• InChiKey: KZMCXHCAMPFQJE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  16
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  52.6
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-benzyloxy-3-oxo-propionic acid ethyl ester 在 sodium hydroxide 、 sodium ethanolate 作用下， 以 乙醇 为溶剂， 反应 5.0h， 生成
  参考文献：
  名称：

  Isocytosine H2-receptor histamine antagonists I. Oxmetidine and related compounds

  摘要：

  DOI：

  10.1016/0223-5234(88)90167-5
• 作为产物：
  描述：

  苯甲醇 在 sodium hydride 作用下， 以 paraffin oil (nujol) 、 乙醚 、 甲苯 、 mineral oil 为溶剂， 反应 6.92h， 生成 2-benzyloxy-3-oxo-propionic acid ethyl ester
  参考文献：
  名称：

  [EN] INHIBITORS OF CATECHOL O-METHYL TRANSFERASE AND THEIR USE IN THE TREATMENT OF PSYCHOTIC DISORDERS
  [FR] INHIBITEURS DE CATÉCHOL O-MÉTHYL TRANSFÉRASE ET UTILISATION ASSOCIÉE DANS LE TRAITEMENT DE TROUBLES PSYCHOTIQUES

  摘要：

  本发明涉及4-吡啶酮化合物，它们是儿茶酚-O-甲基转移酶(COMT)的抑制剂，并且在治疗和预防涉及COMT酶的神经和精神障碍和疾病方面具有用处。本发明还涉及包含这些化合物的药物组合物以及在预防或治疗涉及COMT的这类疾病中使用这些化合物和组合物。

  公开号：

  WO2011109267A1

文献信息

• Novel Pyrimidine Toll-like Receptor 7 and 8 Dual Agonists to Treat Hepatitis B Virus
  作者：David McGowan、Florence Herschke、Frederik Pauwels、Bart Stoops、Stefaan Last、Serge Pieters、Annick Scholliers、Tine Thoné、Bertrand Van Schoubroeck、Dorien De Pooter、Wendy Mostmans、Mourad Daoubi Khamlichi、Werner Embrechts、Deborah Dhuyvetter、Ilham Smyej、Eric Arnoult、Samuël Demin、Herman Borghys、Gregory Fanning、Jaromir Vlach、Pierre Raboisson

  DOI：10.1021/acs.jmedchem.6b00747

  日期：2016.9.8

  Toll-like receptor (TLR) 7 and 8 agonists can potentially be used in the treatment of viral infections and are particularly promising for chronic hepatitis B virus (HBV) infection. An internal screening effort identified a pyrimidine Toll-like receptor 7 and 8 dual agonist. This provided a novel alternative over the previously reported adenine and pteridone type of agonists. Structure–activity relationship

  Toll样受体（TLR）7和8激动剂可以潜在地用于病毒感染的治疗，对于慢性乙型肝炎病毒（HBV）感染特别有希望。内部筛选工作确定了嘧啶Toll样受体7和8双重激动剂。这为先前报道的腺嘌呤和蝶啶酮类型的激动剂提供了新颖的选择。介绍了结构与活性的关系，铅的最优化，计算机对接，药代动力学以及铅化合物离体和体内细胞因子生产的演示。
• Nitrogen-containing heterocyclic compounds, their production and use
  申请人：TAKEDA CHEMICAL INDUSTRIES, LTD.

  公开号：US20020103210A1

  公开（公告）日：2002-08-01

  A compound of the formula: 1 wherein one of A and D is N and the other is C, or both are N; B is N or C; m is 0-3; R 1 , R 2 and R 3 each is (i) H or (ii) a group bound via C, N, O or S; R 4 is a group bound via C; R 5 is H or a group bound via C or O; R 6 is H or a group bound via C; R 7 is a homo- or hetero-cyclic group which may be substituted; or a salt thereof possesses excellent gonadotropin-releasing hormone antagonizing activity, and is useful as a prophylactic or therapeutic agent for sex hormone-dependent diseases, and so forth.

  化合物的公式为1，其中A和D中的一个是N，另一个是C，或者两个都是N；B是N或C；m为0-3；R1，R2和R3各自是（i）H或（ii）通过C，N，O或S结合的基团；R4是通过C结合的基团；R5是H或通过C或O结合的基团；R6是H或通过C结合的基团；R7是可以被取代的同源或异源环状基团；或其盐具有出色的促性腺激素释放激素拮抗活性，并可用作预防或治疗性激素依赖性疾病等的药物。
• INHIBITORS OF CATECHOL O-METHYL TRANSFERASE AND THEIR USE IN THE TREATMENT OF PSYCHOTIC DISORDERS
  申请人：Wolkenberg Scott

  公开号：US20130196002A1

  公开（公告）日：2013-08-01

  The present invention relates to 4-pyridinone compounds which are inhibitors of catechol O-methyltransferase (COMT), and are useful in the treatment and prevention of neurological and psychiatric disorders and diseases in which COMT enzyme is involved. The present invention also relates to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which COMT is involved.

  本发明涉及4-吡啶酮类化合物，它们是儿茶酚-O-甲基转移酶(COMT)的抑制剂，可用于治疗和预防涉及COMT酶的神经和精神障碍和疾病。本发明还涉及包含这些化合物的制药组合物以及在预防或治疗涉及COMT的这些疾病中使用这些化合物和组合物。
• Inhibitors of catechol O-methyl transferase and their use in the treatment of psychotic disorders
  申请人：Wolkenberg Scott

  公开号：US08969364B2

  公开（公告）日：2015-03-03

  The present invention relates to 4-pyridinone compounds which are inhibitors of catechol O-methyltransferase (COMT), and are useful in the treatment and prevention of neurological and psychiatric disorders and diseases in which COMT enzyme is involved. The present invention also relates to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which COMT is involved.

  本发明涉及4-吡啶酮类化合物，其为儿茶酚-O-甲基转移酶（COMT）的抑制剂，可用于治疗和预防神经系统和精神疾病和疾病，其中COMT酶参与。本发明还涉及包含这些化合物的制药组合物以及在预防或治疗COMT参与的这些疾病中使用这些化合物和组合物的用途。
• Pyrimidine compounds
  申请人：SMITH KLINE & FRENCH LABORATORIES LIMITED

  公开号：EP0180298A2

  公开（公告）日：1986-05-07

  Compounds of the formula (I) :- (1) and their salts are histamine H,-antagonists, wher in: R° is 2-guanidinothiazol-4-yl or a group R 1R2N(CHn-Z-wherein R1 and R2 are independently hydrogen, C1-6alkyl, phenyl(C1-6)alkyl, furanyl(C1-6)alkyl, thienyl(C1-8)alkyl, C3-10 cycloalkyl, hydroxy(C2-6)alkyl, or halo(C 2-6)alkyl (wherein said hydroxy and halo groups are not substituted on the carbon atom adjacent to the nitrogen atom); or R1 and R2 together represent - (OH2)r - wherein r is 4 to 7, to form together with the nitrogen atom to which they are attached a 5-8 membered saturated ring; n is an integer from 1 to 6; Z is 2,5-furanyl, 2,5-thienyl, 2,4-pyridyl wherein the R1R2N(CH2)n group is in the 4-position, 2,4-thiazolyl wherein the R1R2N(CH2)n group is in the 2-position, or 1,3- or 1,4-phenylene; m is one; or if Z is pyridyl or phenylene m may also be zero; Y is oxygen, sulphur or methylene; or if Z is furanyl, thienyl or thiazolyl Y may also be a bond; p is two, three or four; q is zero c one; R3 is hydrogen or C1-6alkyl; and R4 is hydrogen, optionally substituted C1-6alkyl, C3-10-cycloalkyl, C3-10CY- cloalkyl(C1-6)alkyl, C2-6alkenyl or C2-6alkynyl,and when q is zero R4 may also be -(CH,)sB wherein s is 1 to 6 and B is optionally substituted aryl or heteroaryl. Pharmaceutical compositions containing them are described as are processes for their preparation.

  式(I):-的化合物 (1) 及其盐类是组胺 H拮抗剂，其中：R° 是 2-胍基噻唑-4-基或基团 R 1R2N(CHn-Z- 其中 R1 和 R2 独立地是氢、C1-6烷基、苯基(C1-6)烷基、呋喃基(C1-6)烷基、噻吩基(C1-8)烷基、C3-10 环烷基、羟基(C2-6)烷基或卤代(C 2-6)烷基（其中所述羟基和卤代基团未在邻近氮原子的碳原子上被取代）；或 R1 和 R2 共同代表-(OH2)r-，其中 r 为 4 至 7，与所连接的氮原子一起形成 5-8 位饱和环；n 为 1 至 6 的整数；Z 是 2,5-呋喃基、2,5-噻吩基、2,4-吡啶基（其中 R1R2N(CH2)n 基团位于 4 位）、2,4-噻唑基（其中 R1R2N(CH2)n 基团位于 2 位）或 1,3-或 1,4-亚苯基；m为1；或者，如果Z为吡啶基或亚苯基，m也可以为0；Y为氧、硫或亚甲基；或者，如果Z为呋喃基、噻吩基或噻唑基，Y也可以是键；p为2、3或4；q为0 c为1；R3为氢或C1-6烷基；R4为氢、任选取代的C1-6烷基、C3-10-环烷基、C3-10CY-环烷基（C1-6）烷基、C2-6烯基或C2-6炔基，当q为0时，R4也可以是-(CH,)sB，其中s为1至6，B为任选取代的芳基或杂芳基。 本文还介绍了含有它们的药物组合物及其制备工艺。